P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

oleh: S. Usmani, A. Hoering, S. Ailawadhi, R. Sexton, B. Lipe, J. Valent, M. Rosenzweig, J. Zonder, M. Dhodapkar, N. Callander, T. Zimmerman, P. Voorhees, B. Durie, S. V. Rajkumar, P. Richardson, R. Orlowski